Axsome Therapeutics Inc will present new data on solriamfetol’s cognitive and wake-promoting effects at the American Academy of Neurology 2024 annual meeting. 

Solriamfetol (brand name Sunosi, Axsome) is approved for patients with excessive daytime sleepiness due to narcolepsy and obstructive sleep apnea.

Details for the presentations are as follows:

Title: Solriamfetol improves cognitive performance in preclinical models of sleep apnea and in a randomized placebo-controlled study of sleep apnea participants (SHARP)
Lead author: David Gozal, MD, MBA, Marie M. and Harry L. Smith Endowed Chair and the chairman of the department of child health at the University of Missouri
Session Name: P9: Sleep 2; Presentation date and time: Wednesday, April 17, from 8 am to 9 am MT
Program Number: P9.004

Title: Solriamfetol for excessive sleepiness in narcolepsy and obstructive sleep apnea: effect sizes and numbers needed to treat or harm
Presentation date and time: Wednesday, April 17, from 11:45 am to 12:45 pm MT
Lead author: Craig Chepke, MD, DFAPA, SUNY Upstate Medical University
Session name: P10: Sleep 3
Program number: P10.009

Title: SURWEY study of solriamfetol: initiation, titration, safety, efficacy, and follow-up experience for patients with OSA in Germany
Presentation date and time: Wednesday, April 17, from 8 am to 9 am MT
Lead author: Yaroslav Winter, MD, University of Medicine Mainz
Session name: P9: Sleep 2
Program number: P9.010

Photo 7579430 © Donkeyru | Dreamstime.com